Acción DMAC DIAMEDICA THERAPEUTICS INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas DiaMedica Therapeutics Inc.

Acciones

DMAC

CA25253X2077

Diferido Nasdaq
Otros sitios de cotización
 16:23:00 14/05/2024 		Varia. Cinco días. Varia. 1 de enero.
3,2 USD +0,31 % Gráfico intradía de DiaMedica Therapeutics Inc. -12,57 % +12,67 %
09/05 Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
17/04 DiaMedica Therapeutics Inc. Anuncia la dosificación del primer paciente en el relanzamiento de su ensayo pivotal de fase /3 ReMEDy2 de DM199 para el tratamiento del ictus isquémico agudo CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics Inc. Announces Executive Changes
DiaMedica Therapeutics Files $100 Million Mixed Shelf
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
Top Premarket Gainers
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción DMAC
  4. Noticias DiaMedica Therapeutics Inc.
  5. Otros idiomas